-
Product Insights
Non-Proliferative Diabetic Retinopathy (NPDR) - Drugs In Development, 2024
Empower your strategies with our Non-Proliferative Diabetic Retinopathy (NPDR) – Drugs In Development, 2024 report and make more profitable business decisions. Non-proliferative diabetic retinopathy (NPDR) is the early stage of the disease in which symptoms will be mild or nonexistent. In NPDR, the blood vessels in the retina are weakened. Tiny bulges in the blood vessels, called microaneurysms, may leak fluid into the retina. This leakage may lead to swelling of the macula. The Non-Proliferative Diabetic Retinopathy (NPDR) drugs in development...
-
Sector Analysis
Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity in 68 Markets - Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033
Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity Market Report Overview The GLP-1R agonists in the type 2 diabetes and obesity market size across the 68M was $39.2 billion in 2023. The GLP-1R agonists in the type 2 diabetes and obesity market will witness significant growth during the forecast period. GLP-1R Agonists in the Type 2 Diabetes and Obesity Market Outlook, 2023-2033 ($ Billion) Buy the Full Report to Know More about the GLP-1R Agonists in the...
-
Thematic Analysis
Digital Marketing Trends in Type 2 Diabetes
Digital Marketing Trends in Type 2 Diabetes Report Overview Novo Nordisk’s Ozempic.com achieved the highest total traffic across branded type 2 diabetes (T2D) patient sites in the US, from April 2023 to March 2024. This was followed by Rybelsus.com. Overall, the highest proportion of traffic to top branded patient T2D websites originated from direct sources, followed by organic sources. There were a few branded sites in the five major European markets (5EU: France, Germany, Italy, Spain, UK) and Canada (EUCAN)...
-
Sector Analysis
Diabetic Nephropathy (DN) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Diabetic Nephropathy (DN) Marketed and Pipeline Drugs Report Overview Diabetic Nephropathy (DN) is glomerular sclerosis and fibrosis caused by the metabolic and hemodynamic changes of diabetes mellitus (DM). It manifests as slowly progressive albuminuria with worsening hypertension and renal insufficiency. DN is the most common cause of nephrotic syndrome in adults and is also the most common cause of end-stage renal disease (ESRD) in the US, accounting for up to 80% of cases. Renal failure is particularly common in certain...
-
Sector Analysis
Painful Diabetic Neuropathy Epidemiology Analysis and Forecast to 2031
Painful Diabetic Neuropathy Market Report Overview The total prevalent cases of Painful Diabetic Neuropathy (PDN) were 7,472,695 cases in the seven major markets (7MM) in 2021 and are expected to achieve an AGR of more than 1% during 2021-2031. Diabetic neuropathy refers to a variety of syndromes that differ in clinical course, distribution, and fiber involvement. Symptoms of diabetic neuropathy vary widely from patient to patient, and some patients with diabetic neuropathy have no symptoms. The PDN market research report...
-
Sector Analysis
Type 2 Diabetes Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2019-2029
Type 2 Diabetes Market Report Overview The T2D market size across the 7MM was valued at $2.43 billion in 2021 and will achieve a CAGR of more than 31% during 2021-2031. The diabetic population is set to grow in line with the increased prevalence of risk factors such as obesity, which will drive market growth during the forecast period. Type 2 Diabetes Market Outlook, 2021-2031 ($ Billion) Buy the Full Report to Gain More Information on the Type 2 Diabetes...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.